Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328444 | 0.87 | — | — | |
| SCHEMBL132643 | 0.87 | — | — | |
| SCHEMBL444373 | 0.87 | — | — | |
| Ethylene Glycol SCHEMBL29006093 | 0.82 | OR51E2 (0.39) | OR51E2 | |
| Acetic Acid SCHEMBL3888013 | 0.80 | OR51E2 (0.50) | OR51E2 | |
| Phosphoric Acid SCHEMBL8540518 | 0.76 | OR51E2 (0.40) | OR51E2 | |
| Methacrylic Acid SCHEMBL10932249 | 0.73 | OR51E2 (0.42) | OR51E2 | |
| Butyl Alcohol SCHEMBL6233982 | 0.73 | ALDH1A1 (0.48) | OR51E2 | |
| Acrylic Acid SCHEMBL4814346 | 0.71 | LMNA (0.42) | OR51E2 | |
| SCHEMBL1331108 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023836-B2 | Use of substituted heterocyclic compounds to control sea lice on fish | NOVARTIS TIERGESUNDHEIT AG (CH) | 2015-05-05 | — | — | US | disclosed |
| EP-2582244-A2 | USE OF SUBSTITUTED HETEROCYCLIC COMPOUNDS TO CONTROL SEA LICE ON FISH | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130095126-A1 | USE OF SUBSTITUTED HETEROCYCLIC COMPOUNDS TO CONTROL SEA LICE ON FISH | NOVARTIS TIERGESUNDHEIT AG (CH) | 2013-04-18 | — | — | US | disclosed |
| WO-2011157733-A2 | NEW USE | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095126-A1 | USE OF SUBSTITUTED HETEROCYCLIC COMPOUNDS TO CONTROL SEA LICE ON FISH | TYR, NISCH, GYPA | OR51E2 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.